Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
91 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Oruka Therapeutics, Inc.’s names, not what it holds today.
Patents granted
91
91 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 1 in 2023
Applications published
57
since 2001, to Dec 31, 2025
Names they are printed under
4
a former name
By yearGrantedApplications published
'09'10'11'12'13'14'15'16'17'18'19'20'21'22'23
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
Medical technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Nuvelo, Inc. a former name
US, as the owner printed on each patent
33 publishedHyseq, Inc. a former name
US, as the owner printed on each patent
10 publishedARCA Biopharma, Inc. a former name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in GB)
7 publishedARCA BIOPHARMA, INC. a former name
named as the applicant on its applications, in US
7 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jan 17, 2023 | 11,554,107 | Methods and compositions involving bucindolol for the treatment of atrial fibrillation | Pharmaceuticals | ARCA Biopharma, Inc. |
| Sep 27, 2022 | 11,452,712 | Methods and compositions involving (S)-bucindolol | Medical technology | ARCA Biopharma, Inc. |
| Feb 23, 2021 | 10,925,856 | Methods and compositions involving bucindolol for the treatment of atrial fibrillation | Pharmaceuticals | ARCA Biopharma, Inc. |
| Sep 19, 2017 | 9,763,916 | Methods and compositions involving (S)-bucindolol | Medical technology | ARCA Biopharma, Inc. |
| Sep 20, 2016 | 9,446,023 | Methods and compositions involving (S)-bucindolol | Medical technology | ARCA Biopharma, Inc. |
| Mar 31, 2015 | 8,993,726 | Antibodies to NTB-A | Pharmaceuticals | ARCA Biopharma, Inc. |
| Feb 3, 2015 | 8,946,284 | Methods and compositions involving (S)-bucindolol | Medical technology | ARCA Biopharma, Inc. |
| May 6, 2014 | 8,715,941 | Antibodies to LRP6 | Pharmaceuticals | ARCA Biopharma, Inc. |
| Sep 17, 2013 | 8,536,310 | Antibodies to CLL-1 | Pharmaceuticals | ARCA Biopharma, Inc. |
| Jun 5, 2012 | 8,193,320 | Antibodies to NTB-A | Pharmaceuticals | ARCA Biopharma, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| May 18, 2023 | 2023/0149354 | METHODS AND COMPOSITIONS INVOLVING BUCINDOLOL FOR THE TREATMENT OF ATRIAL FIBRILLATION | Pharmaceuticals | ARCA Biopharma, Inc. · patent 12,491,177 granted from it |
| Aug 19, 2021 | 2021/0251962 | METHODS AND COMPOSITIONS INVOLVING BUCINDOLOL FOR THE TREATMENT OF ATRIAL FIBRILLATION | Pharmaceuticals | ARCA BIOPHARMA, INC. · patent 11,554,107 granted from it |
| Aug 27, 2020 | 2020/0268710 | METHODS AND COMPOSITIONS INVOLVING BUCINDOLOL FOR THE TREATMENT OF ATRIAL FIBRILLATION | Pharmaceuticals | ARCA Biopharma, Inc. · patent 10,925,856 granted from it |
| Nov 28, 2019 | 2019/0358204 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | Medical technology | ARCA BIOPHARMA, INC. · patent 11,452,712 granted from it |
| Jun 14, 2018 | 2018/0161309 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | Medical technology | ARCA BIOPHARMA, INC. |
| Nov 23, 2017 | 2017/0334989 | ANTIBODIES TO NTB-A | Pharmaceuticals | ARCA BIOPHARMA, INC. |
| Jan 5, 2017 | 2017/0000766 | Methods and Compositions Involving (S)-Bucindolol | Medical technology | ARCA BIOPHARMA, INC. · patent 9,763,916 granted from it |
| Dec 31, 2015 | 2015/0376273 | ANTIBODIES TO NTB-A | Pharmaceuticals | ARCA BIOPHARMA, INC. |
| Jul 9, 2015 | 2015/0190375 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | Medical technology | ARCA BIOPHARMA, INC. · patent 9,446,023 granted from it |
| Aug 7, 2014 | 2014/0220040 | ANTIBODIES TO LRP6 | Pharmaceuticals | ARCA Biopharma, Inc. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.